Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib and Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT03776864Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbralisib in classical Hodgkin lymphoma (cHL), sponsored by University of Washington. Primary endpoint: Complete Response Rate at 1 year. Started Sep 2019; status: terminated.
02
Drugs
umbralisib
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03776864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776864.